Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at HC Wainwright from $231.00 to $239.00. They now have a "buy" rating on the stock.
Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance]
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]